Guggenheim Reiterates Buy Rating on Axsome Therapeutics (AXSM)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Guggenheim Reiterates Buy Rating on Axsome Therapeutics (AXSM)
December 31, 2024 6:37 AM EST
Cantor Fitzgerald analyst Charles C. Duncan raised the price target on Axsome Therapeutics (NASDAQ: AXSM) to $124.00 (from $121.00) while maintaining a Overweight rating.
The analyst comments "AXSM announced topline results from the P3 ACCORD-2 and ADVANCE-2 trials of AXS-05 (approved as AUVELITY in MDD) in Alz Dis agitation (ADA). We acknowledge todays results may be considered mixed, as ADVANCE-2 did not reach stat. sig. (AXSM trading -8% vs. -1% with the XBI). However, we believe that the clear ACCORD-2 data, combined with previously PR'd ADVANCE-1 data... More
December 31, 2024 6:09 AM EST
Mizuho analyst Graig Suvannavejh lowered the price target on Axsome Therapeutics (NASDAQ: AXSM) to $122.00 (from $124.00) while maintaining a Outperform rating.
The analyst comments "Yesterday, AXSM announced highly anticipated P3 data for lead asset AXS-05 in Alzheimer's disease agitation/ADA, a significant, potential... More
December 30, 2024 3:00 PM EST
Leerink Partners analyst Marc Goodman reiterated an Outperform rating and $110.00 price target on Axsome Therapeutics (NASDAQ: AXSM).
The analyst comments "Bottom Line: This was the outcome that we were hoping to avoid, the one that creates the most confusion going forward. Auvelity has a chance to be... More
